LBDA successfully identified KRAS mutations in 37.29% of tumor samples, achieving 88% sensitivity and 100% specificity compared to the NGS method, demonstrating its high accuracy, sensitivity, and translational potential for clinical CRC mutation detection. This evidence concerns the gene KRAS and colorectal carcinoma.